NCT01467310View on ClinicalTrials.gov

Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

March 21, 2016

Study Completion Date

March 21, 2016

Conditions
Breast Cancer
Interventions
DRUG

GSK1120212

1.5 to 2.0 mg taken orally every day for seven days.

Trial Locations (1)

27599

Lineberger Comprehensive Cancer Center, Chapel Hill

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Susan G. Komen Breast Cancer Foundation

OTHER

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT01467310 - Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 | Biotech Hunter | Biotech Hunter